Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| astrocyte | 7 studies | 33% ± 22% | |
| oligodendrocyte precursor cell | 6 studies | 26% ± 5% | |
| glutamatergic neuron | 5 studies | 29% ± 14% | |
| type I pneumocyte | 4 studies | 18% ± 1% | |
| type II pneumocyte | 4 studies | 19% ± 3% | |
| GABAergic neuron | 3 studies | 30% ± 18% | |
| fibroblast | 3 studies | 18% ± 2% | |
| interneuron | 3 studies | 36% ± 16% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 32% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 98% | 114.32 | 566 / 578 | 17% | 0.80 | 202 / 1155 |
| intestine | 81% | 505.81 | 782 / 966 | 24% | 1.65 | 126 / 527 |
| kidney | 96% | 71.15 | 85 / 89 | 3% | 0.05 | 25 / 901 |
| breast | 80% | 41.41 | 366 / 459 | 18% | 3.30 | 198 / 1118 |
| ovary | 94% | 91.22 | 169 / 180 | 1% | 0.02 | 6 / 430 |
| blood vessel | 94% | 106.21 | 1257 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 86% | 57.12 | 559 / 653 | 8% | 0.11 | 49 / 605 |
| adrenal gland | 92% | 61.91 | 238 / 258 | 1% | 0.01 | 2 / 230 |
| bladder | 76% | 32.05 | 16 / 21 | 11% | 0.42 | 56 / 504 |
| prostate | 82% | 53.03 | 200 / 245 | 1% | 0.03 | 3 / 502 |
| uterus | 75% | 47.13 | 128 / 170 | 4% | 0.07 | 19 / 459 |
| esophagus | 60% | 33.85 | 866 / 1445 | 17% | 1.68 | 31 / 183 |
| brain | 72% | 32.67 | 1912 / 2642 | 4% | 0.05 | 26 / 705 |
| heart | 66% | 54.10 | 566 / 861 | 0% | 0 | 0 / 0 |
| adipose | 64% | 27.41 | 774 / 1204 | 0% | 0 | 0 / 0 |
| stomach | 41% | 22.43 | 146 / 359 | 23% | 1.72 | 66 / 286 |
| skin | 40% | 14.44 | 721 / 1809 | 2% | 0.04 | 9 / 472 |
| muscle | 31% | 10.35 | 249 / 803 | 0% | 0 | 0 / 0 |
| spleen | 24% | 6.80 | 57 / 241 | 0% | 0 | 0 / 0 |
| liver | 10% | 2.10 | 22 / 226 | 1% | 0.02 | 5 / 406 |
| pancreas | 4% | 0.96 | 13 / 328 | 5% | 0.29 | 9 / 178 |
| peripheral blood | 1% | 0.27 | 8 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0042632 | Biological process | cholesterol homeostasis |
| GO_0070858 | Biological process | negative regulation of bile acid biosynthetic process |
| GO_0030659 | Cellular component | cytoplasmic vesicle membrane |
| GO_0005794 | Cellular component | Golgi apparatus |
| Gene name | MALRD1 |
| Protein name | MAM and LDL receptor class A domain containing 1 MAM and LDL-receptor class A domain-containing protein 1 |
| Synonyms | DIET1 C10orf112 |
| Description | FUNCTION: Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis. . |
| Accessions | ENST00000377266.7 B7ZBP3 ENST00000454679.7 U5GXS0 H0Y3D6 Q5VYJ5 ENST00000418367.1 ENST00000377265.3 |